Autor: "Hutten SJ" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Autorzy:: Padmanabhan S; The Michael J Fox Foundation for Parkinson's Research, NY, USA.
Lanz TA; Pfizer Inc., Groton, CT, USA.
Gorman D; Pfizer Inc., Cambridge, UK.
Wolfe M; Quanterix, Billerica, MA, USA.
Joyce A; Pfizer Inc., Andover, MA, USA.
Cabrera C; Pfizer Inc., Andover, MA, USA.
Lawrence-Henderson R; Pfizer Inc., Andover, MA, USA.
Levers N; Department of Neurology, Columbia University, NY, USA.
Joshi N; Department of Neurology, Columbia University, NY, USA.
Ma TC; Department of Neurology, Columbia University, NY, USA.
Liong C; Department of Neurology, Columbia University, NY, USA.
Narayan S; Department of Neurology, Columbia University, NY, USA.
Alcalay RN; Department of Neurology, Columbia University, NY, USA.
Hutten SJ; The Michael J Fox Foundation for Parkinson's Research, NY, USA.
Baptista MAS; The Michael J Fox Foundation for Parkinson's Research, NY, USA.
Merchant K; TransThera Consulting Co, Portland, OR, USA.; Pokaż więcej
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2020; Vol. 10 (2), pp. 623-629.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/*metabolism
Leukocytes, Mononuclear/*metabolism
Parkinson Disease/*blood
Parkinson Disease/*genetics
Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Humans ; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/genetics ; Male ; Middle Aged ; Phosphorylation/physiology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
Autorzy:: Merchant KM; Vincere Biosciences, Inc., and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Cedarbaum JM; Biogen, Cambridge, MA, USA.
Brundin P; Van Andel Research Institute, Center for Neurodegenerative Science, Grand Rapids, MI, USA.
Dave KD; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Eberling J; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Espay AJ; UC Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.
Hutten SJ; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Javidnia M; Center for Health and Technology, University of Rochester Medical Center, Rochester, New York, USA.
Luthman J; Eisai, Woodcliff Lake, NJ, USA.
Maetzler W; Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Menalled L; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Reimer AN; The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Stoessl AJ; Djavad Mowafaghian Centre for Brain Health, Pacific Parkinson's Research Center, University of British Columbia, Vancouver, BC, Canada.
Weiner DM; Pokaż więcej
Corporate Authors:: The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group
Źródło:: Journal of Parkinson's disease [J Parkinsons Dis] 2019; Vol. 9 (1), pp. 31-61.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Biomarkers*
Clinical Trials as Topic*
Disease Models, Animal*
Guidelines as Topic*
Proof of Concept Study*
Translational Research, Biomedical*
Parkinson Disease/*drug therapy
alpha-Synuclein/*drug effects
Animals ; Consensus ; Humans ; Parkinson Disease/diagnosis ; Research Design

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Hutten SJ"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Język